Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

Nanobiotix said it has closed its global offering, including the underwriters’ option for additional shares/ADSs. After full option exercise, it issued 2,218,467 ordinary shares (225,373 ADSs plus 33,805 additional ADSs) and 345,099 pre-funded warrants, raising about $100 million (€86.1 million) gross. Net proceeds will fund JNJ-1900 (<10%), Nanoprimer (50–60%), and general purposes (30–40%).

The U.S. approved a potential $24.3B sale of 48 Lockheed Martin F-35 fighter jets to Saudi Arabia, including engines and support equipment. The sale aims to bolster Saudi Arabia's defense capabilities and interoperability with U.S. forces, but faces objections from Israel. The deal is part of broader defense cooperation and Saudi Arabia's military modernization efforts under Vision 2030.

Victory Capital (VCTR) reported $356.469B in assets under management for August, up 3.3% from July, with ETF assets rising 12.4% to $23.474B. The company's second-quarter revenue was $435.4M with a 44.5% operating margin. However, the growth's durability depends on net inflows and fee economics, as market appreciation could have driven some gains.

The U.S. State Department approved a potential $24.3 billion sale of 48 F-35 fighter jets and related equipment to Saudi Arabia, involving Lockheed Martin and Pratt & Whitney. The deal aims to enhance Saudi Arabia's defense capabilities and regional interoperability, supporting U.S. national security objectives.

The US State Department approved a $24.3 billion sale of 48 F-35 fighter jets and related equipment to Saudi Arabia, involving Lockheed Martin and Pratt & Whitney. The sale aims to support US foreign policy and regional stability, according to the department. Congress has 30 days to review the deal. The announcement follows Saudi Arabia's request for US military assistance against Yemen's Houthis, with ongoing diplomatic discussions.

S&P downgraded Corteva Inc. (CTVA) to 'BBB+' from 'A-' due to its upcoming spin-off of the higher-margin seed business, reducing scale and diversification. The company's 2025 crop protection revenues were $7.5B (43% of pre-separation revenue) with EBITDA of $1.35B (34% of pre-separation EBITDA). Corteva targets $2.2B-$2.6B in cash flow from operations in 2027-2029, with priorities including M&A, share repurchases, and dividends.